Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guangxi Univ. TBC1D2 compound A1: sourced facts only. name: "Surprisingly, TBC1 domain family member 2 (TBC1D2) emerged as the selective target of compound A1, which promotes Ras-related protein Rab-7a (RAB7A) accumulation on the lysosomal membrane and facilitates autophagy by inhibiting TBC1D2-mediated guanosine triphosphate (GTP) hydrolysis on RAB7A-GTP." [PMID:42172932]; target: "Surprisingly, TBC1 domain family member 2 (TBC1D2) emerged as the selective target of compound A1, which promotes Ras-related protein Rab-7a (RAB7A) accumulation on the lysosomal membrane and facilitates autophagy by inhibiting TBC1D2-mediated guanosine triphosphate (GTP) hydrolysis on RAB7A-GTP." [PMID:42172932]; developer: "School of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China." [PMID:42172932]; stage: "Finally, A1 proved to be more efficient than matrine in HeLa-infected nude mice and was well-tolerated." [PMID:42172932]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guangxi Univ. TBC1D2 compound A1.